Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$4.26
+8.7%
$5.03
$3.42
$7.20
$220.36M1.821.56 million shs2.29 million shs
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.63
+3.8%
$1.80
$1.32
$2.72
$229.28M1.76205,722 shs97,910 shs
Renovaro Inc. stock logo
RENB
Renovaro
$0.35
-2.4%
$0.34
$0.27
$2.10
$61.57M0.551.52 million shs780,898 shs
Acelyrin, Inc. stock logo
SLRN
Acelyrin
$2.27
$2.29
$1.85
$7.25
$229.17M1.071.28 million shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
+8.67%-8.97%-22.12%-3.84%-10.13%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+3.82%+1.24%-18.09%-12.37%-41.16%
Renovaro Inc. stock logo
RENB
Renovaro
-2.40%+1.66%+9.09%-39.81%-77.76%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
0.00%0.00%0.00%-12.69%-41.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.3103 of 5 stars
0.02.00.00.01.70.80.6
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
1.377 of 5 stars
3.51.00.00.02.70.00.0
Renovaro Inc. stock logo
RENB
Renovaro
2.1303 of 5 stars
0.04.00.00.03.33.30.6
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00329.45% Upside
Renovaro Inc. stock logo
RENB
Renovaro
0.00
N/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
2.40
Hold$9.60322.91% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$246.72M0.97$0.66 per share6.41$7.78 per share0.55
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M46.31N/AN/A$1.05 per share1.55
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/A$0.89 per shareN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/A$6.74 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$1.63M$0.1138.739.68N/A1.32%0.13%0.10%8/6/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Renovaro Inc. stock logo
RENB
Renovaro
-$88.43M-$0.77N/AN/AN/A-60.38%-47.04%N/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%8/12/2025 (Estimated)

Latest RENB, IMMP, ACB, and SLRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11$0.07-$0.04-$0.24$88.85 million$63.34 million
5/14/2025Q1 2025
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$0.95-$0.55+$0.40-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Renovaro Inc. stock logo
RENB
Renovaro
N/AN/AN/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.13
4.31
2.16
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Renovaro Inc. stock logo
RENB
Renovaro
N/A
0.13
0.13
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/A
7.15
7.15

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Renovaro Inc. stock logo
RENB
Renovaro
71.41%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
87.31%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Renovaro Inc. stock logo
RENB
Renovaro
21.72%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,07356.21 million56.21 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Renovaro Inc. stock logo
RENB
Renovaro
20172.12 million134.74 millionOptionable
Acelyrin, Inc. stock logo
SLRN
Acelyrin
135100.95 million86.68 millionOptionable

Recent News About These Companies

Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
Acelyrin: Potential Buyout Led By Concentra Biosciences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$4.26 +0.34 (+8.67%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$4.26 0.00 (-0.07%)
As of 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.63 +0.06 (+3.82%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$1.58 -0.05 (-3.37%)
As of 07:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Renovaro stock logo

Renovaro NASDAQ:RENB

$0.35 -0.01 (-2.40%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$0.35 0.00 (-0.03%)
As of 07:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Acelyrin stock logo

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)
As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.